Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition and changes in metabolic and metabolomic profile in obese patients following 3-week body mass reduction program: a randomized clinical trial

Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition and changes in metabolic and metabolomic profile in obese patients following 3-week body mass reduction program: a randomized clinical trial - Amaranth seed oil and rapeseed oil in weight reduction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00017708

Enrollment

300

Registered

2019-08-05

Start date

2014-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66.0 E78.0

Interventions

Group 1: Rapeseed oil group (group 1) Patients were undergoing to a 3-week body mass reduction program under controlled conditions (3-week hospitalization). During the 3-week body mass reduction pro

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: BMI equal to or greater than 30 kg /m2, stable body weight (<3 kg self-reported change during the previous 3 months)

Exclusion criteria

Exclusion criteria: Exclusion criteria for participation in the study (the presence of even one of the factors): - being on a vegetarian or any another alternative diet, - cancer disease (radiotherapy / chemotherapy) - diabetes mellitus type 1 (T1DM; formerlyinsulin-dependent diabetes or juvenile diabetes) - liver diseases, kidney disease, pancreas diseases, acute coronary artery disease - transplantation or implantation surgery (bypass) - myocardial infarction, ischemic stroke or hemorrhagic stroke - phenylketonuria, galactosemia - autoimmune diseases (autoimmune thyroid disease, celiac disease, haemolytic anemia, vitiligo, Addison's disease, hyperbilirubinemia) - inflammatory bowel disease (Crohn's disease, ulcerative colitis) - pregnancy - mental disorders, eating disorders, ie. anorexia, bulimia - antibiotics, steroids - addiction to drugs, alcohol (consumption of more than 1 serving of alcohol per day)

Design outcomes

Primary

Measure	Time frame
Lab tests, Antropometric measurements, questionnaire At the baseline and at an endpoint we assessed: - biochemical measurements (serum glucose, serum insulin, HOMA, TC, HDL, TG, AlAT), - anthropometric measurement (BMI, WHR, WC, HC) - body mass composition (BIA) - amino acids and proteins profile At the baseline and at an enpoint the changes in nutritional knowledgle was assessed with the use of questionnaire.	—

Measure

Time frame

Lab tests, Antropometric measurements, questionnaire At the baseline and at an endpoint we assessed: - biochemical measurements (serum glucose, serum insulin, HOMA, TC, HDL, TG, AlAT), - anthropometric measurement (BMI, WHR, WC, HC) - body mass composition (BIA) - amino acids and proteins profile At the baseline and at an enpoint the changes in nutritional knowledgle was assessed with the use of questionnaire.

—

Secondary

Measure	Time frame
Statistical analyses were performed using the Statistica 10.0 (StatSoft) program and MetaboAnalyst 3.0. server (www.metaboanalyst.ca).	—

Countries

Poland

Contacts

Public ContactMalgorzata Moszak

Department of Obesity and Metabolic Disorders Treatment and Clinical Dietetics, Karol Marcinkowski University of Medical Sciences, Poznan, Poland

mmoszak@ump.edu.pl+486185493777

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 27, 2026